Afatinib Completed Phase 1 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

CompletedTreatment1 IdentifierTitleDrugs
NCT02191891Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
NCT00993499Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
NCT01090011Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
NCT01647711A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations